Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:15:49.192Z.
Calculation as of: 2026-10-06T14:15:49.192Z.
Quote observation: 2026-10-06T14:15:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69328368594ca01c79a1d7ac3810be200bc4ff9949d0867bb2c2a7ab20a5f204
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Anavex Life Sciences Corp.
Market Cap
$156.15M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.09M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.31M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.23M
Price/FCF Ratio
N/A
TTM Avg
193.13
3Y Avg
193.13
5Y Avg
37.96
Market Cap
$147.84M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.22M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $156.15M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $156.09M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $158.66M | N/A | 69.31 | 47.40 | 57.04 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $153.31M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $152.20M | N/A | 55.06 | 55.06 | 55.06 |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | N/A | 193.13 | 193.13 | 37.96 |
| Korsana Biosciences, Inc. (KRSA)vs › | $147.84M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.22M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $144.85M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
